Stratos Wealth Partners LTD. Takes Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Stratos Wealth Partners LTD. purchased a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 22,457 shares of the biotechnology company’s stock, valued at approximately $241,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AVXL. JPMorgan Chase & Co. raised its holdings in shares of Anavex Life Sciences by 2.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 42,565 shares of the biotechnology company’s stock valued at $242,000 after purchasing an additional 1,191 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Anavex Life Sciences by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 17,980 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 1,671 shares during the period. Foster Victor Wealth Advisors LLC grew its position in Anavex Life Sciences by 5.6% during the fourth quarter. Foster Victor Wealth Advisors LLC now owns 37,663 shares of the biotechnology company’s stock worth $405,000 after buying an additional 2,000 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Anavex Life Sciences by 8.5% in the second quarter. The Manufacturers Life Insurance Company now owns 30,510 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 2,401 shares in the last quarter. Finally, Carnegie Investment Counsel lifted its position in Anavex Life Sciences by 4.7% during the fourth quarter. Carnegie Investment Counsel now owns 76,778 shares of the biotechnology company’s stock worth $825,000 after purchasing an additional 3,445 shares during the period. 31.55% of the stock is owned by institutional investors.

Anavex Life Sciences Price Performance

Anavex Life Sciences stock opened at $8.47 on Friday. Anavex Life Sciences Corp. has a 1 year low of $3.25 and a 1 year high of $14.44. The company has a market capitalization of $718.43 million, a P/E ratio of -16.29 and a beta of 0.69. The business has a 50 day moving average of $9.94 and a 200-day moving average of $7.70.

Anavex Life Sciences (NASDAQ:AVXL) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. Equities analysts anticipate that Anavex Life Sciences Corp. will post -0.73 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $42.00 price target on shares of Anavex Life Sciences in a report on Tuesday, January 28th. D. Boral Capital reissued a “buy” rating and set a $46.00 price objective on shares of Anavex Life Sciences in a report on Wednesday.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.